A Long-Term Open-Label Safety and Effectiveness Trial of Lisdexamfetamine Dimesylate in Adolescents With Attention-Deficit/Hyperactivity Disorder-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Long-Term Open-Label Safety and Effectiveness Trial of Lisdexamfetamine Dimesylate in Adolescents With Attention-Deficit/Hyperactivity Disorder

Published:2013-02 Issue:1 Volume:23 Page:11-21
ISSN:1044-5463
Container-title:Journal of Child and Adolescent Psychopharmacology
language:en
Short-container-title:Journal of Child and Adolescent Psychopharmacology

Author:

Findling Robert L.¹,Cutler Andrew J.²³,Saylor Keith⁴,Gasior Maria⁵,Hamdani Mohamed⁶,Ferreira-Cornwell M. Celeste⁷,Childress Ann C.⁸

Affiliation:

1. Johns Hopkins Medicine and the Kennedy Krieger Institute, Johns Hopkins University, Baltimore, Maryland.

2. Florida Clinical Research Center, LLC, Bradenton, Florida.

3. Department of Psychiatry, University of Florida, Bradenton, Florida.

4. NeuroScience, Inc., Herndon, Virginia.

5. Department of Global Clinical Medicine, Shire Development LLC, Wayne, Pennsylvania.

6. Department of Biostatistics, Shire Development LLC, Wayne, Pennsylvania.

7. Department of Clinical Programs, Shire Development LLC, Wayne, Pennsylvania.

8. Center for Psychiatry and Behavioral Medicine Inc., Las Vegas, Nevada.

Publisher

Mary Ann Liebert Inc

Subject

Pharmacology (medical),Psychiatry and Mental health,Pediatrics, Perinatology and Child Health

Link

http://www.liebertpub.com/doi/pdf/10.1089/cap.2011.0088

Reference45 articles.

1. Adderall XR (package insert). Wayne, PA: Shire US Inc., 2011.

2. Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder

3. Placebo-Controlled Evaluation of Amphetamine Mixture—Dextroamphetamine Salts and Amphetamine Salts (Adderall): Efficacy Rate and Side Effects

4. A community assessment, open-label study of the safety, tolerability, and effectiveness of mixed amphetamine salts extended release in school-age children with ADHD

5. Clinical Practice Guideline: Treatment of the School-Aged Child With Attention-Deficit/Hyperactivity Disorder

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Armodafinil as a Potential Pharmacological Treatment for Attention Deficit Hyperactivity Disorder in Adults: A Review;Current Neuropharmacology;2024-09

2. Lisdexamfetamine dimesylate‐exposition in male rats during the peripubertal period impairs inflammatory mechanisms, antioxidant activity, and apoptosis process in kidneys of male pubertal rats;Journal of Biochemical and Molecular Toxicology;2024-07-25

3. Switch to Lisdexamfetamine in the Treatment of Attention-Deficit Disorder at a Psychiatric Outpatient Clinic for School-Aged Children: A Danish Cohort Study;Journal of Child and Adolescent Psychopharmacology;2024-04-01

4. Treating Executive Function in Youth With Attention Deficit Hyperactivity Disorder: A Review of Pharmacological and Non-Pharmacological Interventions;Journal of Attention Disorders;2024-01-04

5. Review of lisdexamfetamine dimesylate in children and adolescents with attention deficit/hyperactivity disorder;Current Medical Research and Opinion;2020-09-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3